{ "resourceType" : "Bundle", "id" : "08f553cb-1404-4972-bf14-2023a5f59955", "meta" : { "profile" : ["http://fhir.ch/ig/ch-epl/StructureDefinition/ch-idmp-bundle"] }, "type" : "collection", "entry" : [{ "fullUrl" : "http://fhir.epl.bag.admin.ch/CHIDMP/MedicinalProductDefinition/Cuprior-150mg-Filmcoatedtablet", "resource" : { "resourceType" : "MedicinalProductDefinition", "id" : "Cuprior-150mg-Filmcoatedtablet", "meta" : { "profile" : ["http://fhir.ch/ig/ch-epl/StructureDefinition/ch-idmp-medicinalproductdefinition"] }, "text" : { "status" : "extensions", "div" : "
Generated Narrative: MedicinalProductDefinition Cuprior-150mg-Filmcoatedtablet
Profile: MedicinalProductDefinition
CH SMC - Authorized Dose Form: Film-coated tablet
identifier: Medical Product Identifier/CH-01100726-0677190010000
indication:
Cuprior wird angewendet zur Behandlung von Morbus Wilson bei Erwachsenen, Jugendlichen und Kindern im Alter von 5 Jahren oder älter mit Unverträglichkeit gegenüber einer D-Penicillamin-Therapie.
\nlegalStatusOfSupply: Medicinal product subject to medical or veterinary prescription (B)
additionalMonitoringIndicator: No Warning
pediatricUseIndicator: Authorised for the treatment in children
classification: gilteritinib, NA KAS art. 12 para. 5 TPLO, Synthetic, Originator product, 07. STOFFWECHSEL, 07.99. Varia
attachedDocument:
name
productName: Cuprior 150 mg, Filmtabletten
type: FOPH Medicinal Product Name
Usages
- Country Language * Switzerland German (Switzerland)
Generated Narrative: DocumentReference DocRef-FI-Cuprior
Language: de-CH
Profile: DocumentReference
identifier: Application / Assessment Tracking Number/123456789-initial submission-Example-abc-123
status: Current
type: Information for healthcare professionals
date: 2020-09-01 00:00:00+0000
content
Attachments
- Url * https://swissmedicinfo.ch/showText.aspx?textType=FI&lang=DE&authNr=67719&supportMultipleResults=1
Generated Narrative: DocumentReference DocRef-PI-Cuprior
Language: de-CH
Profile: DocumentReference
identifier: Application / Assessment Tracking Number/123456789-initial submission-Example-abc-321
status: Current
type: Patient Information
date: 2020-09-01 00:00:00+0000
content
Attachments
- Url * https://swissmedicinfo.ch/showText.aspx?textType=PI&lang=DE&authNr=67719&supportMultipleResults=1
Generated Narrative: RegulatedAuthorization MA-6771901
Profile: RegulatedAuthorization
identifier: Marketing Authorisation Number/6771901
type: Marketing Authorisation
region: Switzerland
status: valid
statusDate: 2021-01-21
holder: Organization Curatis AG
regulator: Organization Swissmedic Swiss Agency for Therapeutic Products
Generated Narrative: Organization #holder-Curatis-AG
Profile: Organization
identifier: Swissmedic Location Identifier/01100726, LOC Identifier/100082791, GLN Identifier/7640109110007
name: Curatis AG
Generated Narrative: Organization #regulator-SMC
Profile: Organization
identifier: LOC Identifier/100010911, GLN Identifier/7601001398511
name: Swissmedic Swiss Agency for Therapeutic Products
Generated Narrative: PackagedProductDefinition PMP-Cuprior-150mg-Filmcoatedtablet
Profile: PackagedProductDefinition
identifier: Clinical Product Identifier/CH-01100726-0677190010000-0001
containedItemQuantity: 72 Tablet (Details: EDQM - Standard Terms code15054000 = 'Tablet')
description:
CUPRIOR Filmtabl 150 mg 72 Stk
\n| - | Code |
| * | Medicinal product subject to medical or veterinary prescription (B) |
packaging
identifier: Global Trade Item Number/7680677190018
type: Box
quantity: 1
ShelfLifeStorages
- Type Period[x] SpecialPrecautionsForStorage * Shelf life of the medicinal product as packaged for sale No display for Duration (value: 36; unit: month; system: http://unitsofmeasure.org; code: mo) Do not store above 30°C
| - | Type | Value[x] |
| * | Package Size Type | Modal pack |
Generated Narrative: RegulatedAuthorization MA-67719001
Profile: RegulatedAuthorization
identifier: Marketing Authorisation Number/67719001
type: Marketing Authorisation
region: Switzerland
status: valid
statusDate: 2021-01-21
holder: Organization Curatis AG
regulator: Organization Swissmedic Swiss Agency for Therapeutic Products
Generated Narrative: Organization #holder-Curatis-AG
Profile: Organization
identifier: Swissmedic Location Identifier/01100726, LOC Identifier/100082791, GLN Identifier/7640109110007
name: Curatis AG
Generated Narrative: Organization #regulator-SMC
Profile: Organization
identifier: LOC Identifier/100010911, GLN Identifier/7601001398511
name: Swissmedic Swiss Agency for Therapeutic Products
Generated Narrative: RegulatedAuthorization FOPH-21208
Profile: RegulatedAuthorization
CH EPL - Reimbursement SL
url
FOPHDossierNumbervalue: FOPH Dossier Number/21208
url
statusvalue: Reimbursed
url
statusDatevalue: 2021-08-01
url
listingStatusvalue: Listed
url
listingPeriodvalue: 2021-08-01 --> (ongoing)
url
firstListingDatevalue: 2021-08-01
url
costSharevalue: 10
url
gammevalue: Oral
value: CHF3,022.10 (CHF)
type: Ex-factory price
changeType: Price mutation after triennal review of pharmaceuticals
changeDate: 2024-01-01
url
CH EPL - Product Pricevalue: CHF3,347.10 (CHF)
type: Retail price
changeType: VAT-change
changeDate: 2024-01-01
url
CH EPL - Product Price
type: Reimbursement SL
| - | Extension | Reference |
| * | ClinicalUseDefinition: type = indication |
holder: Organization Curatis AG
Generated Narrative: Organization #holder-Curatis-AG
Profile: Organization
identifier: Swissmedic Location Identifier/01100726, LOC Identifier/100082791, GLN Identifier/7640109110007
name: Curatis AG
Generated Narrative: ManufacturedItemDefinition MI-Trientinum-150mg-Filmcoatedtablet
Profile: ManufacturedItemDefinition
status: Active
manufacturedDoseForm: Film-coated tablet
unitOfPresentation: Tablet
Generated Narrative: AdministrableProductDefinition PhP-Trientinum-150mg-Filmcoatedtablet
Profile: AdministrableProductDefinition
status: Active
administrableDoseForm: Film-coated tablet
unitOfPresentation: Tablet
| - | Code |
| * | Oral use |
Generated Narrative: Ingredient Trientinum150
Profile: Ingredient
status: Active
for:
role: Active
substance
Codes
- Concept * Trientine Strengths
- Presentation[x] * 150 mg (Details: UCUM codemg = 'mg')/1 Tablet (Details: EDQM - Standard Terms code15054000 = 'Tablet')
Generated Narrative: ClinicalUseDefinition IND-10061091
Profile: ClinicalUseDefinition Indication
type: Indication
indication
DiseaseSymptomProcedures
- Concept * Wilson's disease IntendedEffects
- Concept * therapeutic
Generated Narrative: ClinicalUseDefinition LIM-79886009-CUPRIOR
type: Indication
indication
DiseaseSymptomProcedures
- Concept * CUPRIOR wird vergütet zur Behandlung der Kupferspeicherkrankheit (Morbus Wilson) bei Erwachsenen, Jugendlichen und Kindern im Alter von 5 Jahren oder älter, die eine Behandlung mit D-Penicillamin nicht vertragen. Die Behandlung muss von Gastroenterologen oder Hepatologen mit Erfahrung bei der Behandlung von Patienten mit Morbus Wilson initiiert und überwacht werden. IntendedEffects
- Concept * therapeutic